| ★ |  Osteoporosis in rare and complex connective tissue diseases | | 96 | — | |
| 15 |  Hydroxychloroquine in connective tissue diseases: benefits and controversial aspects | | 1.8K | — | 72 |
| 16 |  IgG4-related disease (IgG4-RD): update on diagnosis and treatments in 2025 | | 1.3K | — | 72 |
| 11 |  Steroids in Relapsing Polychondritis | | 474 | — | 74 |
| 7 |  How to find hidden Antiphospholipid Syndrome (APS) | | 471 | — | 76 |
| 20 |  CAR-T Therapy in Systemic Lupus Erythematosus (SLE): Explained to the Patient | | 441 | — | 71 |
| 6 |  What is the added value of triple therapy in lupus nephritis? | | 438 | — | 76 |
| 14 |  Why morning joint stiffness and swelling in rheumatic diseases? | | 398 | — | 74 |
| 10 |  Update on B cell targeting therapies in IgG4-related disease | | 375 | — | 75 |
| 4 |  How to explain the antiphospholipid profile to my patients? | | 300 | — | 79 |
| 19 |  2026 focus on monogenic Ehlers-Danlos syndromes: periodontal and vascular variants | | 267 | — | 71 |
| 13 |  Thrombocytopenia in systemic lupus erythematosus (SLE) | | 249 | — | 74 |
| 2 |  Exercise in adult idiopathic inflammatory myopathies (IIMs) | | 188 | — | 81 |
| 9 |  The transition from benign to secondary Raynaud’s phenomenon | | 186 | — | 76 |
| 18 |  The Path to Better Treatments: A Patient-Friendly Guide to Sjögren’s Clinical Trials | | 171 | — | 71 |
| 17 |  Everything you always wanted to know about Ehlers-Danlos Syndromes (EDS) – Part two | | 151 | — | 72 |
| 8 |  Vaccination in undifferentiated connective tissue disease (UCTD) | | 103 | — | 76 |
| 12 |  Obstetric manifestations in past and present antiphospholipid syndrome (APS) classification criteria | | 94 | — | 74 |
| 3 |  Multidisciplinary diagnosis and team treatment in Idiopathic Inflammatory Myopathies | | 64 | — | 79 |
| 5 |  Screening and treatment of systemic sclerosis-associated PAH: where do we stand in 2024? | | 53 | — | 78 |
| 1 |  “Doctor, can you ask me…?” for connective tissue diseases patients | | 46 | — | 81 |